Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up – Should You Buy?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s share price gapped up before the market opened on Friday . The stock had previously closed at $110.38, but opened at $114.15. Kymera Therapeutics shares last traded at $109.1780, with a volume of 25,211 shares.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Canaccord Genuity Group upped their price objective on Kymera Therapeutics from $106.00 to $129.00 and gave the company a “buy” rating in a report on Friday, June 26th. Mizuho boosted their target price on Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. B. Riley Financial upped their price target on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Twenty equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.64.

Kymera Therapeutics Trading Down 0.1%

The firm has a market cap of $9.07 billion, a price-to-earnings ratio of -30.81 and a beta of 1.95. The company has a 50 day moving average of $95.67 and a 200 day moving average of $86.38.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same period in the prior year, the company earned ($0.82) earnings per share. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. Equities analysts forecast that Kymera Therapeutics, Inc. will post -3.28 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Bruce Booth sold 467,878 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $110.29, for a total value of $51,602,264.62. Following the completion of the transaction, the director directly owned 472,267 shares in the company, valued at approximately $52,086,327.43. The trade was a 49.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 80,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total value of $9,223,200.00. Following the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at approximately $76,848,624.72. The trade was a 10.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,637,813 shares of company stock valued at $390,253,404 over the last 90 days. 15.98% of the stock is owned by company insiders.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its stake in Kymera Therapeutics by 27.5% in the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after purchasing an additional 98 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Kymera Therapeutics in the fourth quarter valued at about $63,000. Finally, Osaic Holdings Inc. boosted its position in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.